MEDFORD, Mass. — Sunflower Therapeutics, a public benefit corporation focused on democratizing access to protein manufacturing, has announced its first commercial partnership in Europe through an exclusive distribution agreement with Alflow Scandinavia A/S. The deal grants Alflow the rights to distribute Sunflower’s Daisy Petal™ Perfusion Bioreactor System in Denmark, Norway, Sweden, and Iceland.
The partnership marks a significant step in Sunflower’s international expansion strategy, allowing the company to reach a broader base of scientists and biomanufacturers across the Nordic region.
“Expanding into Europe with a trusted and innovative partner like Alflow allows us to support a broader community of scientists and biomanufacturers,” said Dr. Kerry Love, CEO and co-founder of Sunflower Therapeutics. “Alflow’s team brings a deep technical knowledge that aligns with our ongoing product commercialization goals and our objective of making protein manufacturing more intuitive, cost-effective, and efficient.”
The Daisy Petal™ system is designed for high-efficiency protein production and features a single-use, disposable stirred tank reactor with an integrated in-vessel cell retention device. It enables continuous biomass feeding, fluid harvesting, and perfusion, yielding significantly higher productivity compared to traditional fed-batch fermentation.
“Partnering with Sunflower Therapeutics allows us to bring a truly novel bioreactor solution to the Nordic market,” said Jacob Rosenkrands, CEO of Alflow Scandinavia A/S. “The Daisy Petal system stands out by combining simplicity, scalability, and performance – and we look forward to supporting our customers in bringing it into practice.”
The system is supported by Sunflower’s GMP-compliant bioprocessing software suite, which includes HelianthOS™, Nursery™, and Harvest™. These tools enable automated fermentation workflows, recipe development without coding, and secure data storage—offering a streamlined, intuitive biomanufacturing experience.
